论文部分内容阅读
目的:探讨抗逆转录病毒治疗(anti-retroviral therapy，ART)不同时长对HIV/AIDS患者代谢的影响。方法:单中心横断面研究，选择2020年6月在首都医科大学附属北京地坛医院门诊随诊的424例HIV/AIDS患者，根据不同治疗时长分成四组：Ⅰ组(0.5～2年)、Ⅱ组(2～4年含2年)、Ⅲ组(4～6年含4年)、Ⅳ组(≥6年)，比较各组血脂、肾功、血糖、肝功异常的差异性。结果:高胆固醇血症发生率：Ⅰ组9/106(8.5%)、Ⅱ组17/134(12.7%)、Ⅲ组22/123(17.9%)、Ⅳ组4/61(6.6%)，p＝0.076；高甘油三酯血症发生率：Ⅰ组32/106(30.2%)、Ⅱ组58/134(43.3%)、Ⅲ组50/123(40.7%)、Ⅳ组27/61(44.3%)，p＝0.152；高低密度脂蛋白胆固醇血症发生率：Ⅰ组8/106(7.5%)、Ⅱ组17/134(12.7%)、Ⅲ组15/123(12.2%)、Ⅳ组3/61(4.9%)，p＝0.249；低高密度脂蛋白胆固醇血症发生率：Ⅰ组48/106(45.3%)、Ⅱ组66/134(49.3%)、Ⅲ组55/123(44.7%)、Ⅳ组33/61(54.1%)，p＝0.612；估算肾小球滤过率(eGFR)50 U/L发生率：Ⅰ组23/106(21.7%)、Ⅱ组33/134(24.6%)、Ⅲ组24/123(19.5%)、Ⅳ组12/61(19.7%)，p＝0.761。n 结论:治疗半年以上HIV/AIDS患者血脂紊乱类型以低HDL、高TG血症为主，血脂异常发生率不随治疗时间延长而升高。eGFR随治疗时间延长呈下降趋势并且需关注低磷血症及高尿酸血症的发生。ART药物对肝功的损伤持续存在。“,”Objective:To investigate the effects of different durations of antiretroviral therapy (ART) on metabolism in HIV/AIDS patients.Methods:a single center cross-sectional study, 424 HIV/AIDS were divided into four groups according to the different duration of treatment: group Ⅰ (0.5-2 years), group Ⅱ (2-4 years including 2 years), the group Ⅲ (4-6 years including 4 years), group Ⅳ (≥6 years), the differences of abnormal blood lipid, renal function, blood glucose and liver function in each group were compared.Results:incidence of hypercholesteremia: group Ⅰ 9/106 (8.5%), group Ⅱ 17/134 (12.7%), group Ⅲ 22/123 (17.9%), group Ⅳ 4/61 (6.6%), p=0.076; incidence of hypertriglyceridemia: groupⅠ 32/106 (30.2%), group Ⅱ 58/134 (43.3%), group Ⅲ 50/123 (40.7%), group Ⅳ 27/61 (44.3%), p=0.152; incidence of High LDL-C: group Ⅰ 8/106 (7.5%), group Ⅱ 17/134 (12.7%), group Ⅲ 15/123 (12.2%), group Ⅳ 3/61 (4.9%), p=0.249; Incidence of low HDL-C: groupⅠ 48/106 (45.3%), group Ⅱ 66/134 (49.3%), group Ⅲ 55/123 (44.7%), group Ⅳ 33/61 (54.1%), p=0.612; incidence of glomerular filtration rate 50 U/L: groupⅠ(21.7%), 23 group Ⅱ of 33 (24.6%), group Ⅲ of 24 (19.5%), group Ⅳ of 12 (19.7%), p=0.761Conclusion:The types of dyslipidemia in HIV/AIDS patients treated for more than half a year are mainly low HDL-C and hypertriglyceridemia, and the incidence of dyslipidemia does not increase with the prolonging of treatment. It showed a decreasing trend of eGFR with the prolongation of treatment and the occurrence of hypophosphatemia and hyperuricemia should be concerned. The damage of ART drugs to liver function persisted during treatment.